Most Read Articles
Pearl Toh, 10 May 2017
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.
Audrey Abella, 10 Oct 2017
The SYSADOA* chondroitin sulfate was as effective as the NSAID** celecoxib and superior to placebo in reducing pain and improving function for over 6 months in patients with symptomatic knee osteoarthritis (OA), according to the CONCEPT*** trial.
11 Feb 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) provide potential therapeutic benefits for spinal pain, although the effect does not significantly differ from that provided by placebo, according to a meta-analysis.
06 Jan 2018
Celecoxib at approved dosages show similar or better cardiovascular, gastrointestinal, and renal safety profiles compared with ibuprofen and naproxen in the management of osteoarthritis and rheumatoid arthritis, a recent study has reported.

Pulmonary arterial hypertension, peripheral arterial disease predict VTE in systemic sclerosis

06 Aug 2018

The risk of venous thromboembolism (VTE) in systemic sclerosis (SSc) is similar to that in the general population, according to a recent study. Risk factors for VTE include the presence of pulmonary arterial hypertension (PAH), peripheral arterial disease (PAD), Scl-70 and anticardiolipin antibodies.

In addition, VTE is not an independent predictor of SSc survival.

A total of 1,181 patients with SSs were included, of which 40 (3.4 percent) had VTE events. There was a 2.7 (95 percent CI, 1.9–3.7) cumulative incidence of VTE per 1,000 patient-years.

VTE was predicted by the following: PAH (odds ratio [OR], 3.77; 1.83–8.17), PAD (OR, 5.31; 1.99–12.92), Scl-70 (OR, 2.45; 1.07–5.30) and anticardiolipin antibodies (OR, 5.70; 1.16–21.17). A total of 440 deaths occurred.

Furthermore, no difference in survival was observed between patients with and without VTE (hazard ratio [HR], 1.16; 0.70–1.91). Interstitial lung disease (HR, 1.54; 1.27–1.88) and PAH (HR, 1.35; 1.10–1.65) predicted mortality.

To examine the prevalence, risk factors and effect of VTE on SSc survival, the investigators conducted a cohort study of patients with SSc who fulfilled the American College of Rheumatology/European League Against Rheumatism classification criteria between 1970 and 2017.

Deep vein thrombosis referred to the thrombus on extremity ultrasound, while pulmonary embolism referred to the thrombus on thorax computed tomography angiogram. Finally, the investigators assessed the risk factors for VTE as well as time to all-cause mortality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 May 2017
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.
Audrey Abella, 10 Oct 2017
The SYSADOA* chondroitin sulfate was as effective as the NSAID** celecoxib and superior to placebo in reducing pain and improving function for over 6 months in patients with symptomatic knee osteoarthritis (OA), according to the CONCEPT*** trial.
11 Feb 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) provide potential therapeutic benefits for spinal pain, although the effect does not significantly differ from that provided by placebo, according to a meta-analysis.
06 Jan 2018
Celecoxib at approved dosages show similar or better cardiovascular, gastrointestinal, and renal safety profiles compared with ibuprofen and naproxen in the management of osteoarthritis and rheumatoid arthritis, a recent study has reported.